Phase 1 BAFFR-CAR T Cells: BAFF-R-directed immunotherapy for relapsed B-cell NHL

This study evaluates BAFFR-targeted CAR T cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas—including diffuse large B-cell, follicular, marginal zone, and mantle cell subtypes—using escalation and expansion cohorts to assess safety and early activity. PeproMene Bio, Inc. sponsors the trial at sites in Minneapolis, Duarte, Charlotte, and Seattle.